Publications by authors named "Jidapa Thammasiri"
Article Synopsis
- Hepatocellular carcinoma (HCC) is a dangerous type of cancer that is different inside each tumor, making it hard to treat.
- Researchers studied over 600 samples from 123 patients to understand how this cancer develops and progresses.
- They discovered that the most aggressive cells in a tumor are the best way to predict how well a patient will do, not just by looking at how different the tumor cells are from each other.
Background & Aims: Lifestyle and environmental-related exposures are important risk factors for hepatocellular carcinoma (HCC), suggesting that epigenetic dysregulation significantly underpins HCC. We profiled 30 surgically resected tumours and the matched adjacent normal tissues to understand the aberrant epigenetic events associated with HCC.
Methods: We identified tumour differential enhancers and the associated genes by analysing H3K27 acetylation (H3K27ac) chromatin immunoprecipitation sequencing (ChIP-seq) and Hi-C/HiChIP data from the resected tumour samples of 30 patients with early-stage HCC.
Background: Conventional differential expression (DE) testing compares the grouped mean value of tumour samples to the grouped mean value of the normal samples, and may miss out dysregulated genes in small subgroup of patients. This is especially so for highly heterogeneous cancer like Hepatocellular Carcinoma (HCC).
Methods: Using multi-region sampled RNA-seq data of 90 patients, we performed patient-specific differential expression testing, together with the patients' matched adjacent normal samples.
Article Synopsis
- * A study involving 67 patients with hepatocellular carcinoma (HCC) revealed that while genetic variations remained stable across different cancer stages, phenotypic variations quickly increased, especially in stage II patients, often showing multiple transcriptomic subtypes within a single tumor.
- * The findings indicate that phenotypic ITH is a critical factor for predicting patient outcomes and explains why single-target therapies are often ineffective in HCC, stressing the need for more comprehensive studies on phenotypic evolution in various cancers.
Background: The programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) axis may represent a target for cervical cancer; however, it is poorly understood in human immunodeficiency virus (HIV)-infected patients.
Methods: We evaluated HIV-positive ( = 42) and HIV-negative ( = 110) women with locally advanced cervical cancer regarding their PD-L1 expression, determined by combined positive score (CPS) ⩾ 1 and tumor proportion score (TPS) ⩾ 25%, and PD-L1 copy number alterations, assessed by fluorescence hybridization.
Results: Regardless of HIV status, 84.
Cervical cancer has become a leading cause of death in both HIV-infected and uninfected women. Previous studies have revealed that antiretroviral therapy (ART) possesses anti-human papillomavirus (HPV) and antitumour properties, potentially serving as an anticancer agent and improving functional immunity in HIV-positive individuals. However, to the best of our knowledge, no studies have examined the association between ART and the clinical outcome of patients with pre-existing invasive cervical cancer.
View Article and Find Full Text PDF